| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Internal Medicine The University of Texas Southwestern Medical Center Dallas, Texas 75235-8857
Abnormalities of the human androgen receptor (hAR) cause a range of clinical defects in male development. A large proportion of these mutations are single amino acid substitutions in the hormone-binding domain (HBD) that alter AR function by interfering with the capacity of the AR to bind androgen or to form stable hormone-receptor complexes. Prior studies have suggested that the formation of such stable, active hormone-receptor complexes is a crucial step in the modulation of genes by the AR. It is presumed that these hormone-receptor complexes interact with other proteins to participate in the formation of active transcription complexes at the initiation sites of androgen-responsive genes.
Using a yeast two-hybrid screening method, we isolated a partial cDNA encoding the carboxy terminus of a protein that interacts with the hAR-HBD (amino acid residues 623917) in a ligand-dependent fashion in a yeast two-hybrid assay. Sequence analysis of this clone revealed that it encoded a portion of a protein that had been previously characterized as RFG (RET Fused Gene). Using glutathione-S-transferase (GST) fusions of the hAR HBD and immunoprecipitation of the in vitro translated proteins, we have demonstrated that this interaction can be reproduced in vitro. To determine the capacity of this protein to modulate the activity of the AR in transfection assays, we expressed full-length RFG in the CV1 and DU145 cell lines, in combination with an AR expression vector and model androgen-responsive genes [mouse mammary tumor virus (MMTV) and PRE2-tk luciferase]. Our results demonstrate that RFG alters the induction of these reporter genes very weakly (no greater than 2-fold compared with transfections without the RFG expression plasmid). Thus, while our findings are in agreement with published reports which indicate that RFG interacts with AR-HBD in a ligand-dependent fashion, in our assays RFG does not exert major effects on the activity of the hAR in response to androgen or to other steroid hormones.
This article has been cited by other articles:
![]() |
J. H. Suh, M. Shong, H.-S. Choi, and K. Lee CR6-Interacting Factor 1 Represses the Transactivation of Androgen Receptor by Direct Interaction Mol. Endocrinol., January 1, 2008; 22(1): 33 - 46. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Peng, C. X. Li, F. Chen, Z. Wang, M. Ligr, J. Melamed, J. Wei, W. Gerald, M. Pagano, M. J. Garabedian, et al. Stimulation of Prostate Cancer Cellular Proliferation and Invasion by the Androgen Receptor Co-Activator ARA70 Am. J. Pathol., January 1, 2008; 172(1): 225 - 235. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.-J. Tai, Y.-H. Huang, C.-H. Shih, R.-N. Chen, C.-D. Chen, W.-J. Chen, C.-S. Wang, and K.-H. Lin Direct Regulation of Androgen Receptor-Associated Protein 70 by Thyroid Hormone and Its Receptors Endocrinology, July 1, 2007; 148(7): 3485 - 3495. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Rahman, H. Miyamoto, and C. Chang Androgen Receptor Coregulators in Prostate Cancer: Mechanisms and Clinical Implications Clin. Cancer Res., April 1, 2004; 10(7): 2208 - 2219. [Full Text] [PDF] |
||||
![]() |
M. M. Rahman, H. Miyamoto, H. Takatera, S. Yeh, S. Altuwaijri, and C. Chang Reducing the Agonist Activity of Antiandrogens by a Dominant-negative Androgen Receptor Coregulator ARA70 in Prostate Cancer Cells J. Biol. Chem., May 23, 2003; 278(22): 19619 - 19626. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Powell Jr., L. C. Eisenlohr, and J. L. Rothstein A Thyroid Tumor-Specific Antigen Formed by the Fusion of Two Self Proteins J. Immunol., January 15, 2003; 170(2): 861 - 869. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Li, X. Yu, K. Ge, J. Melamed, R. G. Roeder, and Z. Wang Heterogeneous Expression and Functions of Androgen Receptor Co-Factors in Primary Prostate Cancer Am. J. Pathol., October 1, 2002; 161(4): 1467 - 1474. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. H. Thin, E. Kim, S. Yeh, E. R. Sampson, Y.-T. Chen, L. L. Collins, R. Basavappa, and C. Chang Mutations in the Helix 3 Region of the Androgen Receptor Abrogate ARA70 Promotion of 17beta -Estradiol-induced Androgen Receptor Transactivation J. Biol. Chem., September 20, 2002; 277(39): 36499 - 36508. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Heinlein and C. Chang Androgen Receptor (AR) Coregulators: An Overview Endocr. Rev., April 1, 2002; 23(2): 175 - 200. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z.-x. Zhou, B. He, S. H. Hall, E. M. Wilson, and F. S. French Domain Interactions between Coregulator ARA70 and the Androgen Receptor (AR) Mol. Endocrinol., February 1, 2002; 16(2): 287 - 300. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Lee, S. M. Ramos, A. Ko, D. Masiello, K. D. Swanson, M. L. Lu, and S. P. Balk AR and ER Interaction with a p21-Activated Kinase (PAK6) Mol. Endocrinol., January 1, 2002; 16(1): 85 - 99. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Grad, L. S. Lyons, D. M. Robins, and K. L. Burnstein The Androgen Receptor (AR) Amino-Terminus Imposes Androgen-Specific Regulation of AR Gene Expression via an Exonic Enhancer Endocrinology, March 1, 2001; 142(3): 1107 - 1116. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Evangelou, S. K. Jindal, T. J. Brown, and M. Letarte Down-Regulation of Transforming Growth Factor {beta} Receptors by Androgen in Ovarian Cancer Cells Cancer Res., February 1, 2000; 60(4): 929 - 935. [Abstract] [Full Text] |
||||
![]() |
C. E. Petre, Y. B. Wetherill, M. Danielsen, and K. E. Knudsen Cyclin D1: Mechanism and Consequence of Androgen Receptor Co-repressor Activity J. Biol. Chem., January 11, 2002; 277(3): 2207 - 2215. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |